(NASDAQ: HLVX) Hillevax's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Hillevax's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast HLVX's revenue for 2028 to be $1,972,549,458, with the lowest HLVX revenue forecast at $1,972,549,458, and the highest HLVX revenue forecast at $1,972,549,458. On average, 2 Wall Street analysts forecast HLVX's revenue for 2029 to be $3,047,573,870, with the lowest HLVX revenue forecast at $1,905,360,432, and the highest HLVX revenue forecast at $4,189,787,308.
In 2030, HLVX is forecast to generate $6,248,328,690 in revenue, with the lowest revenue forecast at $6,016,927,680 and the highest revenue forecast at $6,479,729,701.